Flagship Journal

Yann Le Cam Chief | Executive Officer, EURORDIS-Rare Diseases Europe. The conference happens every 2 years and the purpose is to formulate strategies at a national, international, and European level. The conference also provides an opportunity to look at legislative and non-legislative policies and learn about the latest research. The scope is broad, covering the entire spectrum of rare diseases.

Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer.

Multisystem inflammatory syndrome (MIS-C) is a challenging disease associated with COVID-19. Clinical manifestation of MIS-C may mimic many endemic illnesses of tropical and subtropical countries, making early diagnosis more difficult.

Diencephalic syndrome (DS), first described by Russell in 1951, is a rare cause of failure to thrive in infants and young children with preservation of linear growth.

THE IMPACT of climate change is clear, urgent, and formidable, with the effects of climate change on health an immediate threat to…

GLOBALLY, hospital-based care has a substantial ecological footprint. In the USA, the health sector generates approximately 10% of the…

Any filler injection requires a bespoke treatment approach and a thorough anatomy knowledge to minimise procedural risks and achieve…

Worldwide, tobacco use causes more than 7 million deaths every year, a death toll that could increase to 8 million by the end of the…